COVID-19 spike variants antigen Recombinant 2019-nCoV(SARS-CoV-2) Spike S-trimer protein (S1+S2 trimer, C-6His) with furin cleavage site mutation (R682G, R683S, R685S) & T4 fibritin trimerization motif

Order information

Package	Catalog No.	Price(In USD)	Qty (Quantity)	Sum(In USD)
1mg	GMP-V-2019nCoV-S-trimer-001-1mg	5990
10mg	GMP-V-2019nCoV-S-trimer-001-10mg	38790
100mg	GMP-V-2019nCoV-S-trimer-001-100mg	258000
≥100mg	GMP-V-2019nCoV-S-trimer-001-xmg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Accession Number	QHD43415.1
Expression platform	2019-nCoV(SARS-CoV-2, SARS2-coronavirus)
Isotypes	Mamamlian (human cell)
Tag	C-His
Products description	Recombinant 2019-nCoV(SARS-CoV-2)e Spike Protein S1+S2 domain was expressed in mammanlian cell (human cells)expression system. The target gene encoding Met1-Gln1208 was expressed with 6 HIS tag at the C-terminus.S1/S2 cleavage site (furin cleavage sequence) mutation of PRRAR to PGSAS at residues 682–685(R682G,R683S,R685S) are introduced to bolish the furin cleavage site.T4 fibritin trimerization motif is added to C-terminal of the protein to improve the stability of spike trimer protein.
Bioactivity validation	ACE2 binding; Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays;
Purity	Purity: ≥95% (SDS-PAGE)
Application	Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies Immunogen in Elisa,lateral-flow tests,and other immunoassays; Standard substance The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
predicted Molecular Mass	136kDa
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

COVID-19 recombinant SARS-CoV2 (2019 nCoV coronavirus) antigen:
Recombinant 2019-nCoV(SARS-CoV-2) Spike S-trimer protein (S1+S2 trimer, C-6His)

Recombinant 2019-nCoV(SARS-CoV-2)e Spike Protein S1+S2 domain was expressed in mammanlian cell (human cells)expression system. The target gene encoding Met1-Gln1208 was expressed with 6 HIS tag at the C-terminus.S1/S2 cleavage site (furin cleavage sequence) mutation of PRRAR to PGSAS at residues 682–685(R682G,R683S,R685S) are introduced to bolish the furin cleavage site.T4 fibritin trimerization motif is added to C-terminal of the protein to improve the stability of spike trimer protein.

Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies.

Validated in functional ELISA, other immunoassays, the antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.

Information of SARS-CoV-2 (2019nCOV) Spike protein trimer

The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection.The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell entry and is the dominant target of the immune system. The highly flexible Spike protein (S-protein), with its mobile domains, transitions from closed to open conformations to expose its receptor-binding site and, subsequently, from prefusion to postfusion conformations to mediate fusion of viral and cellular membranes. SARS-CoV-2 (2019nCoV) Spike protein (S-protein) derivatives are components of vaccine candidates and diagnostic assays, as well as tools for research into the biology and immunology of SARS-CoV-2.

GeneMedi designed Spike trimer protein, which is descripted as below:

The thermostable, disulfide-bonded Spike-protein trimers construct we make is:
1) S1/S2 cleavage site (furin cleavage sequence) mutant: Modification of the coding sequence of the multibasic S1/S2 cleavage site (furin cleavage sequence) PRRAR to PGSAS at residues 682–685 (R682G, R683S, R685S).
2) Trimerization statues: add exogenous trimerization signal peptides: T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus.

It has been demonstrated that the designed, thermostable, closed Spike trimer can be used in serological assays in COVID-19 test. This trimer protein has potential applications as a reagent for serology, virology and as an immunogen of COVID-19 related diagnostics and vaccine development.

GeneMedi also offers pre-made gene ORF mutation plasmids of Spike trimer mutation(thermostable, disulfide-bonded Spike-protein trimers).

The pre-made gene ORF vector of Spike trimer mutation is Codon Optimized for mamamlian and can be used for mammalian expression.

GeneMedi also provides pre-made the lentivirus, adenovirus and AAV vector for the gene ORF plasmids of 2019 nCoV (SARS2 coronavirus).

Reference:
Xiong X, Qu K, Ciazynska KA, Hosmillo M, Carter AP, Ebrahimi S, Ke Z, Scheres SHW, Bergamaschi L, Grice GL, Zhang Y; CITIID-NIHR COVID-19 BioResource Collaboration, Nathan JA, Baker S, James LC, Baxendale HE, Goodfellow I, Doffinger R, Briggs JAG. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat Struct Mol Biol. 2020 Oct;27(10):934-941. doi: 10.1038/s41594-020-0478-5. Epub 2020 Jul 31. PMID: 32737467; PMCID: PMC7116388.